A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the recommended phase 2 dose (RP2D) regimen(s) of JNJ-78306358 in Part 1 (Dose Escalation) and to determine the safety of JNJ-78306358 at the RP2D regimen(s) in Part 2 (Dose Expansion).

Clinical Trial Description

JNJ-78306358 is a bispecific antibody binding to CD3 on T cells and human leukocyte antigen G (HLA-G) on cancer cells. The study consists of a screening phase, a treatment phase, and a post-treatment follow-up phase. Study evaluations include safety, pharmacokinetics, biomarkers, immunogenicity, and efficacy (disease evaluations). The total study duration will be up to 2 years 4 months. ;

Study Design

Related Conditions & MeSH terms

Neoplasms

Clinical Trial Details

NCT number	NCT04991740
Study type	Interventional
Source	Janssen Research & Development, LLC
Contact
Status	Completed
Phase	Phase 1
Start date	October 24, 2021
Completion date	February 9, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03826043` - THrombo-Embolic Event in Onco-hematology	N/A
Terminated	`NCT03166631` - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread	Phase 1
Completed	`NCT01938846` - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors	Phase 1
Recruiting	`NCT06058312` - Individual Food Preferences for the Mediterranean Diet in Cancer Patients	N/A
Completed	`NCT03308942` - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants	Phase 2
Recruiting	`NCT06018311` - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads	N/A
Withdrawn	`NCT05431439` - Omics of Cancer: OncoGenomics
Completed	`NCT01343043` - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma	Phase 1
Completed	`NCT01938638` - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer	Phase 1
Recruiting	`NCT05514444` - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)	Phase 1
Recruiting	`NCT02292641` - Beyond TME Origins	N/A
Terminated	`NCT00954512` - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)	Phase 1/Phase 2
Recruiting	`NCT04958239` - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)	Phase 1
Recruiting	`NCT04627376` - Multimodal Program for Cancer Related Cachexia Prevention	N/A
Completed	`NCT01222728` - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting	`NCT06004440` - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting	`NCT05636696` - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue	N/A
Not yet recruiting	`NCT06035549` - Resilience in East Asian Immigrants for Advance Care Planning Discussions	N/A
Recruiting	`NCT06004466` - Noninvasive Internal Jugular Venous Oximetry
Completed	`NCT02909348` - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab